The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.The past few days have been very pleasant for biotech company Amylyx Pharmaceuticals (AMLX -3.92%). As is often the case with companies in that sector, Amylyx's stock has recently seen a dramatic rise thanks to news from the laboratory. The company's stock was rising by a bit over 10% week to date as of Friday before market open, according to data compiled by S&P Global Market Intelligence.Tackling a rare disord ...